Susvimo

Do not take it if

From the package leaflet in EMA’s product information, p. 32.

How to take it

These directions are for this exact strength and form. Another one is different.

• Before you are given Susvimo your doctor will check that you respond to medicine that attaches to and blocks ‘VEGF’.
• How much and how often Susvimo is given  The recommended dose is 2 mg given gradually by the implant.
•  The implant is refilled every 24 weeks - roughly 6 months - by your doctor.
• Based on how you respond to treatment with Susvimo, your doctor may give additional injections into your eye in the 24-week refill period.
• How you will be given Susvimo An eye surgeon trained in the implant procedures will fill the implant with Susvimo before inserting the implant in your eye. After, the implant will be refilled by your eye doctor (trained in the refill procedure) at regular times.
•  Your doctor(s) will inject medicine, to numb the eye for both of these procedures.
•  Your doctor will perform an aseptic or sterile procedure to reduce the risk of infection. See section 2 ‘Monitoring and care during your treatment with Susvimo’.
• Susvimo must only be given using the implant meant for this medicine.
• How long you will keep the implant The implant is intended to remain in the eye, unless removed for medical reasons. Your doctor will keep track of your illness to check the treatment is working properly. They may need to stop the refills of Susvimo or safely remove the implant using surgery (if medically necessary).
• If you miss a dose (refill) of Susvimo If you miss a refill, book a new appointment with your doctor to get the refill as soon as possible. Do not wait until the next planned refill.
• Before stopping treatment with Susvimo If you are considering stopping Susvimo, make sure you discuss this with your doctor, as they will need to discuss with you about monitoring your eye and the need to retain or remove the implant. Your doctor will discuss other treatments to determine the best one for you. Stopping all treatment may increase your risk of vision loss and your vision may get worse.
• If you have any further questions on the use of this medicine, ask your doctor.

From the package leaflet in EMA’s product information, p. 35.

Warnings and precautions

From the package leaflet in EMA’s product information, p. 32–34.

Pregnancy and breastfeeding

From the package leaflet in EMA’s product information, p. 34.

Other medicines

From the package leaflet in EMA’s product information, p. 34.

Driving and using machines

• You may have worse vision for a while after the implant is inserted, removed, refilled with medicine, or after eye examinations.
• Do not drive or use machines until your doctor tells you to remove the eye shield - and the reduced vision is better.
• Susvimo contains polysorbate 20 This medicine contains 0.002 mg polysorbate 20 per 0.02 mL dose. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

From the package leaflet in EMA’s product information, p. 34–35.

Side effects

• Like all medicines, this medicine can cause side effects, although not everybody gets them.
• The list of possible side effects includes those related to Susvimo, the implant in the eye and the procedures to place, refill and remove the implant.
• Some side effects may be serious Tell your doctor immediately if you notice any of the following serious side effects – you may need urgent medical or surgical treatment, or a delay before your next refill:
• Very common: may affect more than 1 in 10 people.
• Common: may affect up to 1 in 10 people.
• Uncommon: may affect up to 1 in 100 people.
•  more moving spots or “spider webs” in your vision. You may have bleeding in the gel-like substance at the back of the eye (vitreous haemorrhage) - common  a sudden feeling that something is in your eye, eye discharge or watering. This feeling may mean:
• a small bulge in the layer that covers the white part of the eye (conjunctival bleb) - very common
• fluid leaking creating a blister-like bulge on the surface of the eye (conjunctival bleb leak) - very common
• the layer that covers the white part of your eye is wearing away (conjunctival erosion), which can expose the implant - common
• stitches are opening to make a gap in the layer that covers the white of the eye (conjunctival retraction). This could expose the implant - common  worsening eye pain with vision loss, sensitivity to light, or redness in the white of the eye. This might be an infection of the eyeball with inflammation inside of the eye (endophthalmitis) - common  flashing lights, a change or loss of vision. This may mean:
• You have a hole or tear in the layer (the retina) in the back of the eye that senses light (retinal tear) - uncommon
• You have separation of the layer (the retina) in the back of the eye where light is sensed (retinal detachment) - common  clouding of the lens of the eye due to injury (traumatic cataract) - uncommon  the implant has moved out of place (device dislocation) - common If you notice any of the serious side effects above, tell your doctor immediately.
• Other side effects Most of the side effects are mild to moderate.
• Tell your doctor if any of the following side effects become severe:
• Very common: may affect more than 1 in 10 people  blood in the layer that covers the white of the eye (conjunctival haemorrhage)
•  redness in the layer that covers the white of the eye (conjunctival hyperaemia)
•  inflammation of the coloured part of the eye (iritis)
•  eye pain  clouding of the lens of the eye (cataract)
•  moving spots in the vision (vitreous floaters)
•  headache  implant damage Common: may affect up to 1 in 10 people  bleeding at the back of the eye  sensation that something is in the eye  eye irritation or discomfort - burning, stinging, itching, tearing, redness  nausea, vomiting  lowered pressure inside the eye  when the gel-like substance at the back of the eye (vitreous) shrinks and separates from the layer (retina) at the back of the eye that senses light (vitreous detachment)
•  vision blurred or less sharp  swelling of the eyelid, clear part at the front of the eye or the layer that covers the white part of the eye  inflammation of the eyelid - redness, pain, swelling and itching of the eyelids or eyelid scales  scratched eye surface (corneal abrasion)
•  drooping of the upper eyelid  itchy eyes  thinning of the white part of the eye  defect of the clear part (cornea) at the front of the eye  eye discharge, increased production of tears, or watering eyes  eyes feeling more sensitive to light  infection of the layer that covers the white of the eye (conjunctivitis)
•  pain during the procedure  inflammation of the gel-like substance at the back of the eye (vitritis)
•  separation of the layer of blood vessels from underneath the white part of the eye (choroidal detachment)
•  bruising around the eye following surgery  blood in front of the coloured part (the iris) of the eye  inflammation of the coloured part of the eye (the iris) and its nearby tissue  thinning of the layer that covers the white part of the eye  attachment of the coloured part of the eye (the iris) to other structures in the eye (iris adhesions)
•  defect of the layer that covers the white part of the eye Uncommon: may affect up to 1 in 100 people  cloudiness of the implant  redness in the white part of the eye  exposed stitches – or other problems after the implant procedure  discomfort after a refill at or near where the implant is, or discomfort after the procedure  scar tissue formation where the implant was inserted (fibrosis)
•  a reaction (for example swelling) at or near where the implant is  foreign object in the eye  swelling after the procedure If any of these side effects become severe, please tell your doctor.
• Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.
• By reporting side effects, you can help provide more information on the safety of this medicine.

From the package leaflet in EMA’s product information, p. 35–37.

How to store it

• The following information is intended for healthcare professionals.
• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.
• Store in a refrigerator (2 °C – 8 °C).
• Do not freeze.
• Keep the vial in the outer carton in order to protect from light.
• Prior to use, the unopened vial may be kept at 9 °C to 30 °C for up to 24 hours.

From the package leaflet in EMA’s product information, p. 37–38.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Report wrong or outdated information on this page

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Ranibizumab